Cytion and AsedaSciences Partner for Early Safety Prediction with Target Driven Cell Model Selection

Cytion and AsedaSciences have formed a partnership to enhance early safety prediction in R&D using target-driven cell model selection. Their collaboration leverages the ,,3RnD® platform, which connects targets, compounds, and authenticated human cell models. This integration aims to significantly reduce manual searching and empower researchers to make earlier, more informed decisions during the drug discovery and development process, ultimately streamlining the assessment of potential drug safety.

Cytion and AsedaSciences have announced a strategic partnership focused on supporting early safety prediction through innovative target-driven cell model selection. This collaboration is designed to revolutionize the initial stages of drug discovery and development by making safety assessments more efficient and accurate. The cornerstone of this partnership is the utilization of the ,,3RnD® platform, an advanced system that seamlessly connects specific biological targets, chemical compounds, and authenticated human cell models. This sophisticated integration capability is crucial for providing a comprehensive and relevant context for evaluating drug candidates.The primary benefits of this alliance include a substantial reduction in the manual effort typically required for research and development processes. By automating the connection between various critical data points, the platform enables scientists to identify potential safety concerns much earlier in the development cycle. This proactive approach facilitates more informed decision-making, which is vital for preventing costly late-stage failures and accelerating the progression of promising drug candidates. The partnership underscores a commitment to enhancing the reliability and speed of drug development, ultimately aiming to bring safer and more effective therapies to market more rapidly by optimizing the initial safety profiling stages.